Wells downgrades Vertex to Equal Weight on lack of catalysts
Wells Fargo analyst Mohit Bansal downgraded Vertex Pharmaceuticals (VRTX) to Equal Weight from Overweight with an unchanged price target of ...
Piramal Pharma Ltd: Piramal Pharma Limited Announces Results for Q3 and 9M FY25
Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals and wellness company, today ...
Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds
Total proceeds of $530 million on $300 million original 2022 investment Proceeds strengthen balance sheet and provide added flexibility to pursue ...
Endometriosis Clinical Trial Pipeline Gains Momentum as 15+ Key Companies at the Forefront | DelveInsight
DelveInsight's 'Endometriosis Pipeline Insight 2025' report provides comprehensive global coverage of pipeline endometriosis ...
DelveInsight Business Research, LLP: Endometriosis Clinical Trial Pipeline Gains Momentum as 15+ Key Companies at the Forefront | DelveInsight
Approximately 10% of women of reproductive age worldwide are affected by endometriosis, equating to about 190 million individuals. This substantial patient population necessitates effective ...